| Document |
Document Title |
|
WO/2021/047672A1 |
Disclosed herein are triterpenoid compounds, for example, a compound of Formula (I), and pharmaceutical compositions thereof. Also disclosed herein are methods of their use for treat.
|
|
WO/2021/016191A1 |
Disclosed herein are compounds of the formula: (I) wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidan...
|
|
WO/2020/259205A1 |
Disclosed are derivatives of novel pentacyclic triterpenoid AMPK agonists, oleanolic acid and δ-oleanolic acid, and medicinal use thereof, specifically, a compound represented by formula I or formula II, and a pharmaceutically acceptabl...
|
|
WO/2020/264509A1 |
Provided herein is a compound of Formula I, II, IlIa, IlIb, V, VIa, VIb, VII, VIII, IX, or XI: or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of Formula I, II, IlIa, IlIb, V, VIa, VIb, VI...
|
|
WO/2020/264512A1 |
Provided herein in part is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of Formula I, and methods of using the compounds, e.g, in the treatment of CNS- relate...
|
|
WO/2020/264495A1 |
Provided herein is a compound of Formula (1-I): or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R11a, R11b, R16a, R16b, R19, R18, X, q, r, s, t, u, and n are defined herein. Also provided here...
|
|
WO/2020/253814A1 |
The present application relates to a class of tripterine derivatives represented by formula I, a preparation method therefor and the use thereof. The tripterine derivatives have a significant Prdx1 inhibitory activity, can be used for pr...
|
|
WO/2020/221113A1 |
Provided by the present invention is a preparation method for momordin Ib, comprising: first, mixing a plant containing a triterpene saponin derivative having the structural unit shown in formula (I) or a plant extract containing a trite...
|
|
WO/2020/198883A1 |
Transdermal medicaments containing cannabidiol (CBD) for use in the amelioration of conditions, including anxiety, depression, pain, inflammation, epilepsy, parkinson's disease, oxidative injury and nausea; and a method for preparing same.
|
|
WO/2020/180661A1 |
This disclosure relates to extracts from chestnut plants and compositions comprising compounds contained therein. In certain embodiments, the extracts are derived from the leaves of a Castanea plant. In certain embodiments, the disclosur...
|
|
WO/2020/165742A1 |
The present invention relates to novel triterpenone derivatives of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. The invention also relates to novel triterpenone deri...
|
|
WO/2020/165741A1 |
The present invention relates to novel triterpene derivatives of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and ring are as defined herein. The invention also relates to novel triterpene derivativ...
|
|
WO/2020/163642A1 |
The present invention provides a compound of formula (I) or a salt thereof: (F ormula (I)) wherein X, L, V, R1, R2, R3 and R4, are as defined herein. The claimed compounds inhibit the enzyme 11-hydroxysteroid dehydrogenase type 2 (11-HSD...
|
|
WO/2020/161221A1 |
The present invention relates to a method for the production of a (poly)hydroxylated pentacyclic triterpene composition including a 3-O-p-coumaroyl ester of tormentic acid from a plant suspension cell culture, to a pharmaceutical composi...
|
|
WO/2020/143640A1 |
The present invention relates to a steroid compound, and a use thereof and a preparation method therefor. It is expected that such compound can effectively treat mental and neurological diseases, and has good active efficacy, pharmacokin...
|
|
WO/2020/121161A1 |
The present invention relates to the mesylate (CH3SO2) salt of the following compound (I).
|
|
WO/2020/096486A1 |
The invention relates to the field of medicine and to the chemical and pharmaceutical industry, and concerns agents for treating cancer. 3-O-sulfamate-16,16-dimethyl-D-homoequilenin is proposed as an anti-cancer agent in monotherapy and ...
|
|
WO/2020/068689A1 |
Described herein are terpinoid derivatives as NRF2 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of inflammatory diseases.
|
|
WO/2020/006510A1 |
The present invention concerns novel pharmaceutically active triterpene amine derivatives, pharmaceutical compositions containing the same, their use as medicaments, and the use of the compounds for the manufacture of specific medicament...
|
|
WO/2019/207460A1 |
The present invention relates to compound of Formula I or a pharmaceutically acceptable salt thereof (Formula I) wherein R1 is Formula (AA) or Formula (BB) where the squiggly line indicates the point of attachment to the rest of the mole...
|
|
WO/2019/186342A1 |
The present invention discloses certain ionic liquid salts of 4-(((3aR,5aR,5bR,7aR,9S,11aR,11bR,13aS)-3a-((R) -2-((4-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-1- hydroxyethyl)-1-isopropyl-5a,5b,8,8,1 1 a-pentamethyl-2- oxo-3,3a,4,5,5a,...
|
|
WO/2019/191637A1 |
Methods of preventing or retarding or reversing or abolishing the onset of Parkinson's and other neurodegenerative diseases are discussed.
|
|
WO/2019/126761A1 |
Provided herein is a compound of Formula (I-I) or a pharmaceutically acceptable salt thereof, wherein t, R7, R3, R9, R6a, R6b, R11a, R11b, R15a, R15b, R16a, R16b, R17a, R17b, R18a, R18b, R19a, R19b, R5a, R5b, R8 and R13 are defined herei...
|
|
WO/2019/079160A1 |
The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and ...
|
|
WO/2019/060051A1 |
The present invention provides a compound of formula (I) or a salt thereof: (I) wherein X, L, V, R1, R2, R3 and R4, are as defined herein. These compounds are inhibitors of 11-hydroxysteroid dehydrogenase type 2 (11-HSD-2) and are used t...
|
|
WO/2019/052560A1 |
Disclosed are a pentacyclic triterpene compound as shown in general formula (I) and a preparation method therefor. The compound has an effective antagonistic effect on FXR receptors.
|
|
WO/2019/054379A1 |
The present invention pertains to a compound represented by formula (I) or a salt thereof. [In formula (I), ring C is a hydrocarbon ring, etc.; the hydrocarbon ring, etc., has a substituent group selected from the group consisting of hyd...
|
|
WO/2018/237135A3 |
Disclosed is a novel process for the isolation of bioactive compounds from Terminalia arjuna. More specifically, the invention discloses a process for isolation and enrichment of bioactive compounds Arjunic acid, Arjunolic acid, Arjungen...
|
|
WO/2019/018940A1 |
Natural sweetener compositions are disclosed, which generally include steviol glycosides extracted from a Stevia rebaudiana plant and an amino acid component consisting of free glycine. The natural sweetener compositions may optionally f...
|
|
WO/2019/014412A1 |
Disclosed are crystalline polymorphs of Bardoxolone methyl, and pharmaceutical compositions thereof.
|
|
WO/2018/113285A1 |
Disclosed is a method for preparing sodium aescinate, relating to the technical field of plant extraction. The method comprises: semen aesculi is taken and subjected to alcohol extraction, the resulting extracting solution is subjected t...
|
|
WO/2018/103766A1 |
Disclosed is a compound as shown in formula I. Also disclosed are a synthesis method for the compound, and uses of the compound in the preparation of anti-cancer and anti-inflammatory drugs and a drug which treats hepatitis C.
|
|
WO/2018/063010A9 |
The invention relates to a novel lupeol derivative, which is the ester of 4-picolinic acid (isonicotinic acid) and 20(29)-lupen-3.beta.-ol (lupeol), having structural Formula (1). The novel lupeol derivative is a result of modification o...
|
|
WO/2018/088439A1 |
Provided are: a compound represented by formula (I); a retinoid metabolic pathway inhibitor comprising the same; an agent for increasing the ratio of memory T cells; a prophylactic and/or therapeutic agent for cancer or an infectious dis...
|
|
WO/2018/073551A1 |
The present invention relates to a chemical composition characterized in that it comprises: - the molecule A or a physiologically acceptable salt thereof, and/or: - the molecule B or a physiologically acceptable salt thereof, said molecu...
|
|
WO/2018/069086A1 |
Triterpenoid derivatives and compositions comprising said triterpenoids derivatives of Formula (I) are described, wherein R=-C(O)NHOH. Said triterpenoids and compositions show capacity to bind PHD2, stabilize HIF-1α and HIF-2α proteins...
|
|
WO/2017/053868A8 |
Disclosed herein are C4 modified oleanolic acid derivatives of the formula: Formula (X) or Formula (XII), as well as analogs thereof, wherein the variables are defined herein. In addition, disclosed herein are pharmaceutical compositions...
|
|
WO/2018/063010A1 |
The invention relates to a novel lupeol derivative, which is the ester of 4-picolinic acid (isonicotinic acid) and 20(29)-lupen-3.beta.-ol (lupeol), having structural Formula (1). The novel lupeol derivative is a result of modification o...
|
|
WO/2017/215678A3 |
Provided is a cefaclor pharmaceutical composition. The cefaclor pharmaceutical composition comprises cefaclor and a naturally produced compound (I) having a new structure and isolated from dry roots and stems of Acorus tatarinowii. When ...
|
|
WO/2017/220050A3 |
Disclosed are an azithromycin pharmaceutical composition and a medical use thereof for cough relief. The azithromycin pharmaceutical composition contains azithromycin and a natural product compound (I) separated from dried rhizoma arisae...
|
|
WO/2018/025462A1 |
Provided is a method for economically and easily producing soya saponins without crushing seeds or plant bodies or treating with an organic solvent. The method for producing soya saponins comprises: incubating or growing a legume plant b...
|
|
WO/2018/006804A1 |
Provided are an application of a compound represented by formula I as a ligand of an orphan nuclear receptor Nur77, and an application for preventing or treating a disease related to the orphan nuclear receptor Nur77.
|
|
WO/2018/006801A1 |
The present application relates to an orphan nuclear receptor Nur77 ligand and an application thereof. The application specifically relates to a compound represented by formula I and application of the compound as the orphan nuclear rece...
|
|
WO/2018/002849A1 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, triterpenoid compounds that possess unique antiviral activity are provided as HIV maturation inhibitor...
|
|
WO/2017/220050A2 |
Disclosed are an azithromycin pharmaceutical composition and a medical use thereof for cough relief. The azithromycin pharmaceutical composition contains azithromycin and a natural product compound (I) separated from dried rhizoma arisae...
|
|
WO/2017/215678A2 |
Disclosed are a cefaclor pharmaceutical composition and effects thereof for protecting acute lung injuries. The cefaclor pharmaceutical composition provided in the present invention comprises cefaclor and a naturally produced compound (I...
|
|
WO/2017/210636A1 |
The disclosure relates to compositions, methods, and kits comprising glycyrrhetinic acid derivatives for selectively eradicating cancer cells (e.g., leukemic cells) in a population or subject, and related methods of treating cancer (e.g....
|
|
WO/2017/185273A1 |
A method for preparing saikoside from bupleurum longiradiatum, comprising: washing bupleurum longiradiatum, picking out impurities from the bupleurum longiradiatum, air-curing the bupleurum longiradiatum, and grinding the bupleurum longi...
|
|
WO/2017/177326A1 |
The invention provides conjugates that comprise a targeting moiety, a nucleic acid, and optional linking groups as well as synthetic intermediates and synthetic methods useful for preparing the conjugates. The conjugates are useful to ta...
|
|
WO/2016/178092A8 |
Formula (I) The invention relates to C-3 novel triterpenone with C-28 reverse amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated dise...
|
